FibroGen/ US31572Q8087 /
2024-04-25 9:59:54 PM | Chg. +0.03 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.02USD | +3.11% | 24,544 Turnover: 24,632.87 |
-Bid Size: - | -Ask Size: - | 1.02 | 0.91 |
GlobeNewswire
04-24
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire
04-02
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire
02-26
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZenec...
GlobeNewswire
02-05
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program ...
GlobeNewswire
01-25
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action ...
GlobeNewswire
2023-12-09
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower ...
GlobeNewswire
2023-12-08
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, A...
GlobeNewswire
2023-11-30
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
GlobeNewswire
2023-08-29
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambul...
GlobeNewswire
2022-02-04
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
GlobeNewswire
2021-11-15
EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel